

# Sacha Gnjatic

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/308035/sacha-gnjatic-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

227  
papers

20,578  
citations

68  
h-index

142  
g-index

269  
ext. papers

25,250  
ext. citations

10.9  
avg, IF

6.22  
L-index

#	Paper	IF	Citations
227	Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2005</b> , 102, 18538-43	11.5	1722
226	Immunologic correlates of the abscopal effect in a patient with melanoma. <i>New England Journal of Medicine</i> , <b>2012</b> , 366, 925-31	59.2	1503
225	An inflammatory cytokine signature predicts COVID-19 severity and survival. <i>Nature Medicine</i> , <b>2020</b> , 26, 1636-1643	50.5	895
224	Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. <i>New England Journal of Medicine</i> , <b>2008</b> , 358, 2698-703	59.2	702
223	Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses. <i>Cell</i> , <b>2017</b> , 169, 750-765.e17	56.2	629
222	Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2010</b> , 107, 7875-80	11.5	580
221	Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. <i>Immunity</i> , <b>2016</b> , 44, 924-38	32.3	544
220	Cancer classification using the Immunoscore: a worldwide task force. <i>Journal of Translational Medicine</i> , <b>2012</b> , 10, 205	8.5	538
219	Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. <i>Nature</i> , <b>2017</b> , 551, 512-516	50.4	533
218	Radiotherapy induces responses of lung cancer to CTLA-4 blockade. <i>Nature Medicine</i> , <b>2018</b> , 24, 1845-1854	50.5	379
217	Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2004</b> , 101, 10697-702	11.5	373
216	CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2007</b> , 104, 3967-72	11.5	354
215	Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2014</b> , 189, 832-44	10.2	340
214	The abscopal effect associated with a systemic anti-melanoma immune response. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2013</b> , 85, 293-5	4	304
213	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , <b>2014</b> , 5, 12472-508	3.3	301
212	Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. <i>Cancer Research</i> , <b>2011</b> , 71, 5670-7	10.1	294
211	CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 20410-5	11.5	291

210	Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 8055-62	12.9	285
209	Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2011</b> , 108, 16723-8	11.5	270
208	NY-ESO-1: review of an immunogenic tumor antigen. <i>Advances in Cancer Research</i> , <b>2006</b> , 95, 1-30	5.9	265
207	CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens. <i>Nucleic Acids Research</i> , <b>2009</b> , 37, D816-9	20.1	257
206	Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C). <i>Cell</i> , <b>2020</b> , 183, 982-995.e14	56.2	248
205	Single-cell immune landscape of human atherosclerotic plaques. <i>Nature Medicine</i> , <b>2019</b> , 25, 1576-1588	50.5	247
204	Single-Cell Analysis of Crohn's Disease Lesions Identifies a Pathogenic Cellular Module Associated with Resistance to Anti-TNF Therapy. <i>Cell</i> , <b>2019</b> , 178, 1493-1508.e20	56.2	219
203	Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2007</b> , 104, 12837-42	11.5	212
202	Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. <i>Journal of Immunology</i> , <b>2008</b> , 181, 776-84	5.3	207
201	Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 6497-508	12.9	201
200	Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2006</b> , 103, 14453-8	11.5	182
199	Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. <i>Journal of Experimental Medicine</i> , <b>2000</b> , 191, 625-30	16.6	182
198	NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. <i>Cancer Research</i> , <b>2003</b> , 63, 6076-83	10.1	173
197	RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. <i>Blood</i> , <b>2008</b> , 111, 1357-65	2.2	170
196	Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2003</b> , 100, 8862-7	11.5	168
195	Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. <i>Journal of Immunology</i> , <b>2004</b> , 172, 3289-96	5.3	160
194	Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2012</b> , 109, 5797-802	11.5	153
193	CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. <i>Blood</i> , <b>2005</b> , 106, 1008-11	2.2	151

192	Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. <i>Journal of Immunology</i> , <b>2000</b> , 165, 948-55	5.3	148
191	PD-L1 as a biomarker of response to immune-checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , <b>2021</b> , 18, 345-362	19.4	148
190	Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer. <i>Cancer Immunology Research</i> , <b>2014</b> , 2, 37-49	12.5	144
189	Seromic profiling of ovarian and pancreatic cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2010</b> , 107, 5088-93	11.5	141
188	Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 1650-5	11.5	141
187	The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2015</b> , 191, 377-90	10.2	140
186	Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy <b>2017</b> , 5, 44		139
185	Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. <i>Blood</i> , <b>2007</b> , 109, 1103-12	2.2	138
184	In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines. <i>Journal of Clinical Investigation</i> , <b>2006</b> , 116, 1946-54	15.9	127
183	Ipilimumab for patients with advanced mucosal melanoma. <i>Oncologist</i> , <b>2013</b> , 18, 726-32	5.7	117
182	Toll-like receptor agonists: are they good adjuvants?. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2010</b> , 16, 382-91	2.2	115
181	A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma. <i>Sarcoma</i> , <b>2013</b> , 2013, 168145	3.1	114
180	Consensus nomenclature for CD8 T cell phenotypes in cancer. <i>Oncotmunology</i> , <b>2015</b> , 4, e998538	7.2	101
179	Coronavirus 2019 and People Living With Human Immunodeficiency Virus: Outcomes for Hospitalized Patients in New York City. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 71, 2933-2938	11.6	100
178	Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma. <i>Journal of Immunotherapy</i> , <b>2012</b> , 35, 89-97	5	100
177	Host tissue determinants of tumour immunity. <i>Nature Reviews Cancer</i> , <b>2019</b> , 19, 215-227	31.3	94
176	Tertiary Lymphoid Structure-Associated B Cells are Key Players in Anti-Tumor Immunity. <i>Frontiers in Immunology</i> , <b>2015</b> , 6, 67	8.4	94
175	In-depth tissue profiling using multiplexed immunohistochemical consecutive staining on single slide. <i>Science Immunology</i> , <b>2016</b> , 1, aaf6925	28	93

174	Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity. <i>Journal of Immunology</i> , <b>2011</b> , 186, 1218-27	5.3	88
173	Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 2740-8 <sup>9</sup>	12.9	85
172	NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors. <i>Cancer Research</i> , <b>2004</b> , 64, 2199-204	10.1	85
171	Pathophysiology of SARS-CoV-2: targeting of endothelial cells renders a complex disease with thrombotic microangiopathy and aberrant immune response. The Mount Sinai COVID-19 autopsy experience		80
170	CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2002</b> , 99, 11813-8	11.5	79
169	Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge Napoli, December 5th 2015 <b>2016</b> , 4,		78
168	Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival. <i>International Journal of Cancer</i> , <b>2010</b> , 126, 909-18	7.5	78
167	Fr492 SIGNIFICANTLY REDUCED MORTALITY IN COVID-19 PATIENTS WITH GASTROINTESTINAL MANIFESTATIONS. <i>Gastroenterology</i> , <b>2021</b> , 160, S-330	13.3	78
166	IMMU-60. MAPPING TUMORAL AND IMMUNE HETEROGENEITY IN PD-1 RESPONSIVE GLIOBLASTOMA. <i>Neuro-Oncology</i> , <b>2018</b> , 20, vi135-vi135	1	78
165	A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward. <i>Journal of Hematology and Oncology</i> , <b>2020</b> , 13, 94	22.4	76
164	Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients. <i>Cancer Immunology Research</i> , <b>2013</b> , 1, 235-44	12.5	75
163	Chemoradiotherapy-induced upregulation of PD-1 antagonizes immunity to HPV-related oropharyngeal cancer. <i>Cancer Research</i> , <b>2014</b> , 74, 7205-16	10.1	74
162	Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2002</b> , 99, 10629-34	11.5	70
161	Regulatory T cell-resistant CD8+ T cells induced by glucocorticoid-induced tumor necrosis factor receptor signaling. <i>Cancer Research</i> , <b>2008</b> , 68, 5948-54	10.1	69
160	NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 2130-9	12.9	68
159	Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes. <i>European Urology</i> , <b>2018</b> , 73, 751-759	10.2	67
158	NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer. <i>PLoS ONE</i> , <b>2012</b> , 7, e38783	3.7	66
157	Seromic analysis of antibody responses in non-small cell lung cancer patients and healthy donors using conformational protein arrays. <i>Journal of Immunological Methods</i> , <b>2009</b> , 341, 50-8	2.5	65

156	Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)–correlation with prognostic factors. <i>Cancer Immunity</i> , <b>2007</b> , 7, 11		65
155	Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. <i>Journal of Clinical Investigation</i> , <b>2002</b> , 110, 1813-22	15.9	64
154	Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma. <i>Cancer Immunology Research</i> , <b>2015</b> , 3, 278-287	12.5	63
153	The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 6946-55	12.9	61
152	Direct tumor recognition by a human CD4(+) T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses. <i>Scientific Reports</i> , <b>2015</b> , 5, 14896	4.9	60
151	Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments. <i>European Journal of Immunology</i> , <b>2004</b> , 34, 2919-29	6.1	60
150	Pathophysiology of SARS-CoV-2: the Mount Sinai COVID-19 autopsy experience. <i>Modern Pathology</i> , <b>2021</b> , 34, 1456-1467	9.8	59
149	Quantification of hepatocellular carcinoma heterogeneity with multiparametric magnetic resonance imaging. <i>Scientific Reports</i> , <b>2017</b> , 7, 2452	4.9	58
148	Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma. <i>Blood</i> , <b>2012</b> , 119, 3097-104	2.2	58
147	Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies. <i>Gastroenterology</i> , <b>2021</b> , 161, 715-718.e4	13.3	55
146	The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation <b>2020</b> , 8,		54
145	Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial. <i>Cancer Immunology Research</i> , <b>2013</b> , 1, 340-50	12.5	53
144	NY-ESO-1 expression and immunogenicity in esophageal cancer. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 6551-8.9	12.9	53
143	Prostate cancer progression correlates with increased humoral immune response to a human endogenous retrovirus GAG protein. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 6112-25	12.9	50
142	Influence of CD4+CD25+ regulatory T cells on low/high-avidity CD4+ T cells following peptide vaccination. <i>Journal of Immunology</i> , <b>2006</b> , 176, 6340-6	5.3	50
141	PLAC1, a trophoblast-specific cell surface protein, is expressed in a range of human tumors and elicits spontaneous antibody responses. <i>Cancer Immunity</i> , <b>2007</b> , 7, 18		49
140	Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF. <i>Journal of Immunotherapy</i> , <b>2008</b> , 31, 849-57	5	48
139	Expression and immune responses to MAGE antigens predict survival in epithelial ovarian cancer. <i>PLoS ONE</i> , <b>2014</b> , 9, e104099	3.7	48

138	Cross-presentation of HLA class I epitopes from exogenous NY-ESO-1 polypeptides by nonprofessional APCs. <i>Journal of Immunology</i> , <b>2003</b> , 170, 1191-6	5.3	46
137	Monitoring CD4+ T cell responses against viral and tumor antigens using T cells as novel target APC. <i>Journal of Immunological Methods</i> , <b>2003</b> , 278, 57-66	2.5	45
136	Intestinal Host Response to SARS-CoV-2 Infection and COVID-19 Outcomes in Patients With Gastrointestinal Symptoms. <i>Gastroenterology</i> , <b>2021</b> , 160, 2435-2450.e34	13.3	45
135	Autoantibodies against cancer antigens. <i>Methods in Molecular Biology</i> , <b>2009</b> , 520, 11-9	1.4	43
134	An inflammatory cytokine signature helps predict COVID-19 severity and death <b>2020</b> ,		43
133	NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer. <i>Gynecologic Oncology</i> , <b>2017</b> , 145, 420-425	4.9	42
132	Phase I clinical trial of mixed bacterial vaccine (Coley's toxins) in patients with NY-ESO-1 expressing cancers: immunological effects and clinical activity. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 5449-59	12.9	42
131	NY-CO-58/KIF2C is overexpressed in a variety of solid tumors and induces frequent T cell responses in patients with colorectal cancer. <i>International Journal of Cancer</i> , <b>2010</b> , 127, 381-93	7.5	41
130	Intracellular tumor-associated antigens represent effective targets for passive immunotherapy. <i>Cancer Research</i> , <b>2012</b> , 72, 1672-82	10.1	40
129	Cancer-testis antigens and immunosurveillance in human cutaneous squamous cell and basal cell carcinomas. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 3562-70	12.9	40
128	A Frameshift in CSF2RB Predominant Among Ashkenazi Jews Increases Risk for Crohn's Disease and Reduces Monocyte Signaling via GM-CSF. <i>Gastroenterology</i> , <b>2016</b> , 151, 710-723.e2	13.3	40
127	First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 5808-5817	12.9	38
126	First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient. <i>Journal of Immunotherapy</i> , <b>2017</b> , 40, 302-306	5	38
125	Clinical trial of the intratumoral administration of labeled DC combined with systemic chemotherapy for esophageal cancer. <i>Journal of Immunotherapy</i> , <b>2012</b> , 35, 513-21	5	38
124	In vitro stimulation of CD8 and CD4 T cells by dendritic cells loaded with a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein: Identification of a new HLA-DR15-binding CD4 T-cell epitope. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 1921-7	12.9	38
123	LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer. <i>Cancer Immunity</i> , <b>2007</b> , 7, 16		38
122	Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4(+) T cells. <i>Cancer Immunology Research</i> , <b>2014</b> , 2, 341-50	12.5	37
121	Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination. <i>International Journal of Cancer</i> , <b>2012</b> , 130, 584-92	7.5	36

120	MRI radiomics features predict immuno-oncological characteristics of hepatocellular carcinoma. <i>European Radiology</i> , <b>2020</b> , 30, 3759-3769	8	35
119	Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma. <i>Journal of Immunotherapy</i> , <b>2007</b> , 30, 847-54	5	35
118	Mapping and ranking of potential cytotoxic T epitopes in the p53 protein: effect of mutations and polymorphism on peptide binding to purified and refolded HLA molecules. <i>European Journal of Immunology</i> , <b>1995</b> , 25, 1638-42	6.1	34
117	NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus. <i>International Journal of Cancer</i> , <b>2015</b> , 136, E590-601	7.5	33
116	Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. <i>Cancer Immunity</i> , <b>2003</b> , 3, 19		33
115	Expression of cancer testis antigen CT45 in classical Hodgkin lymphoma and other B-cell lymphomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2010</b> , 107, 3093-8	11.5	32
114	Characterization of preexisting MAGE-A3-specific CD4+ T cells in cancer patients and healthy individuals and their activation by protein vaccination. <i>Journal of Immunology</i> , <b>2009</b> , 183, 4800-8	5.3	32
113	IFN-gamma enables cross-presentation of exogenous protein antigen in human Langerhans cells by potentiating maturation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2004</b> , 101, 14467-72	11.5	32
112	Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy. <i>Cancer Immunity</i> , <b>2010</b> , 10, 1		32
111	MAGE-A3 is highly expressed in a subset of colorectal cancer patients. <i>Cancer Immunity</i> , <b>2012</b> , 12, 16		32
110	Trypanosoma cruzi as an effective cancer antigen delivery vector. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2011</b> , 108, 19695-700	11.5	29
109	Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients. <i>Cancer Immunity</i> , <b>2010</b> , 10, 4		29
108	Heat shock protein 90-mediated peptide-selective presentation of cytosolic tumor antigen for direct recognition of tumors by CD4(+) T cells. <i>Journal of Immunology</i> , <b>2012</b> , 188, 3851-8	5.3	28
107	Ex-vivo analysis of CD8+ T cells infiltrating colorectal tumors identifies a major effector-memory subset with low perforin content. <i>Journal of Clinical Immunology</i> , <b>2006</b> , 26, 447-56	5.7	28
106	Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 450-464	12.9	28
105	NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer. <i>Cancer Immunity</i> , <b>2003</b> , 3, 10		28
104	Induction of regulatory T cell-resistant helper CD4+ T cells by bacterial vector. <i>Blood</i> , <b>2008</b> , 111, 1404-12.2		27
103	Tumor-reactive CD8+ T-cell clones in patients after NY-ESO-1 peptide vaccination. <i>International Journal of Cancer</i> , <b>2007</b> , 121, 2042-8	7.5	25



102	Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma. <i>Cancer Cell</i> , <b>2021</b> , 39, 1442-1444	24.3	25
101	Cancer/testis antigen expression and autologous humoral immunity to NY-ESO-1 in gastric cancer. <i>Cancer Immunity</i> , <b>2004</b> , 4, 11		23
100	Phase II trial of gemcitabine + cisplatin + ipilimumab in patients with metastatic urothelial cancer.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 357-357	2.2	20
99	Recognition of naturally processed and ovarian cancer reactive CD8+ T cell epitopes within a promiscuous HLA class II T-helper region of NY-ESO-1. <i>Cancer Immunology, Immunotherapy</i> , <b>2008</b> , 57, 1185-95	7.4	19
98	Gastrointestinal involvement attenuates COVID-19 severity and mortality <b>2020</b> ,		19
97	Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma. <i>Cancer Immunology Research</i> , <b>2020</b> , 8, 70-80	12.5	19
96	Th1/Th2 CD4+ T cell responses against NY-ESO-1 in HLA-DPB1*0401/0402 patients with epithelial ovarian cancer. <i>Cancer Immunity</i> , <b>2004</b> , 4, 12		19
95	Immunotherapy biomarkers 2016: overcoming the barriers <b>2017</b> , 5, 29		17
94	Therapeutic administration of a synthetic CpG oligodeoxynucleotide triggers formation of anti-CpG antibodies. <i>Cancer Research</i> , <b>2012</b> , 72, 4304-10	10.1	17
93	MAGE expression in head and neck squamous cell carcinoma primary tumors, lymph node metastases and respective recurrences-implications for immunotherapy. <i>Oncotarget</i> , <b>2017</b> , 8, 14719-14733	3.3	16
92	Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C) <b>2020</b> ,		16
91	Immunohistochemical Detection of $\gamma$ T Lymphocytes in Formalin-fixed Paraffin-embedded Tissues. <i>Applied Immunohistochemistry and Molecular Morphology</i> , <b>2019</b> , 27, 581-583	1.9	16
90	Prognostic value of immune cells in the tumor microenvironment of early-stage lung cancer: a meta-analysis. <i>Oncotarget</i> , <b>2019</b> , 10, 7142-7155	3.3	15
89	First-in-human phase 1 dose-escalating trial of G305 in patients with advanced solid tumors expressing NY-ESO-1. <i>Cancer Immunology, Immunotherapy</i> , <b>2019</b> , 68, 1211-1222	7.4	14
88	Immune biomarkers are more accurate in prediction of survival in ulcerated than in non-ulcerated primary melanomas. <i>Cancer Immunology, Immunotherapy</i> , <b>2015</b> , 64, 1193-203	7.4	14
87	Split T cell tolerance against a self/tumor antigen: spontaneous CD4+ but not CD8+ T cell responses against p53 in cancer patients and healthy donors. <i>PLoS ONE</i> , <b>2011</b> , 6, e23651	3.7	14
86	Multiplexed Immunohistochemical Consecutive Staining on Single Slide (MICSSS): Multiplexed Chromogenic IHC Assay for High-Dimensional Tissue Analysis. <i>Methods in Molecular Biology</i> , <b>2020</b> , 2055, 497-519	1.4	14
85	Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51. <i>Cancer Immunity</i> , <b>2002</b> , 2, 12		14

84	Expression and clinical significance of MAGE and NY-ESO-1 cancer-testis antigens in adenoid cystic carcinoma of the head and neck. <i>Head and Neck</i> , <b>2016</b> , 38, 1008-16	4.2	13
83	A multimodal imaging workflow to visualize metal mixtures in the human placenta and explore colocalization with biological response markers. <i>Metallomics</i> , <b>2016</b> , 8, 444-52	4.5	13
82	Inducing efficient cross-priming using antigen-coated yeast particles. <i>Journal of Immunotherapy</i> , <b>2008</b> , 31, 607-19	5	13
81	Cancer/testis antigens expression and autologous serological response in a set of Brazilian non-Hodgkin's lymphoma patients. <i>Cancer Immunology, Immunotherapy</i> , <b>2012</b> , 61, 2207-14	7.4	12
80	Downregulation of exhausted cytotoxic T cells in gene expression networks of multisystem inflammatory syndrome in children. <i>Nature Communications</i> , <b>2021</b> , 12, 4854	17.4	12
79	BRAF-induced senescence drives Langerhans cell histiocytosis pathophysiology. <i>Nature Medicine</i> , <b>2021</b> , 27, 851-861	50.5	11
78	Identification of new NY-ESO-1 epitopes recognized by CD4+ T cells and presented by HLA-DQ B1 03011. <i>International Journal of Cancer</i> , <b>2006</b> , 118, 668-74	7.5	10
77	Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity.. <i>Science Translational Medicine</i> , <b>2022</b> , 14, eabm7853	17.5	10
76	Cancer-testis antigen 7 expression and immune responses following allogeneic stem cell transplantation for multiple myeloma. <i>Cancer Immunology Research</i> , <b>2014</b> , 2, 547-58	12.5	9
75	Immune response, safety, and survival impact from CMB305 in NY-ESO-1+ recurrent soft tissue sarcomas (STS).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 11006-11006	2.2	9
74	Evaluation of LAGE-1 and NY-ESO-1 expression in multiple myeloma patients to explore possible benefits of their homology for immunotherapy. <i>Cancer Immunity</i> , <b>2011</b> , 11, 1		9
73	A novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapy. <i>Cancer Immunity</i> , <b>2013</b> , 13, 3		9
72	Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 4287-4300	12.9	9
71	A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 2470-2480	12.9	9
70	Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. <i>Blood</i> , <b>2021</b> , 137, 3212-3217	2.2	9
69	Overcoming regulatory T-cell suppression by a lyophilized preparation of Streptococcus pyogenes. <i>European Journal of Immunology</i> , <b>2013</b> , 43, 989-1000	6.1	8
68	Sampling the host response to SARS-CoV-2 in hospitals under siege. <i>Nature Medicine</i> , <b>2020</b> , 26, 1157-1158	50.5	8
67	Autologous Lymphocyte Infusion Supports Tumor Antigen Vaccine-Induced Immunity in Autologous Stem Cell Transplant for Multiple Myeloma. <i>Cancer Immunology Research</i> , <b>2019</b> , 7, 658-669	12.5	8

66	A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1. <i>Onc Immunology</i> , <b>2020</b> , 9, 1847846	7.2	7
65	Long-term complete remission following radiosurgery and immunotherapy in a melanoma patient with brain metastasis: immunologic correlates. <i>Cancer Immunology Research</i> , <b>2014</b> , 2, 404-9	12.5	7
64	Cancer Immunotherapy: From local to global. <i>Nature Nanotechnology</i> , <b>2017</b> , 12, 840-841	28.7	7
63	Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial.. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2022</b> ,	18.8	7
62	Recombinant (rec) MAGE-A3 Protein Immunotherapy and Peripheral Blood Lymphocyte (PBL) Reconstitution Induce Strong Antigen-Specific Humoral and Cellular Immune Responses in Patients Undergoing Autologous Stem Cell Transplantation (ASCT) for Consolidation of Multiple Myeloma (MM). <i>Blood</i> , <b>2014</b> , 124, 1184-1184	2.2	7
61	Phase I, first-in-human trial of LV305 in patients with advanced or metastatic cancer expressing NY-ESO-1.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3021-3021	2.2	7
60	A streamlined whole blood CyTOF workflow defines a circulating immune cell signature of COVID-19. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , <b>2021</b> , 99, 446-461	4.6	7
59	Spatial CRISPR genomics identifies regulators of the tumor microenvironment.. <i>Cell</i> , <b>2022</b> ,	56.2	7
58	A Streamlined CyTOF Workflow To Facilitate Standardized Multi-Site Immune Profiling of COVID-19 Patients <b>2020</b> ,		6
57	Proliferation of HIV-infected renal epithelial cells following virus acquisition from infected macrophages. <i>Aids</i> , <b>2020</b> , 34, 1581-1591	3.5	6
56	Serological response to COVID-19 vaccination in IBD patients receiving biologics		6
55	DNA damage response (DDR) gene mutations (mut), mut load, and sensitivity to chemotherapy plus immune checkpoint blockade in urothelial cancer (UC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 300-300	2.2	5
54	Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume I-conceptual challenges <b>2020</b> , 8,		5
53	HLA superfamily assignment is a predictor of immune response to cancer testis antigens and survival in ovarian cancer. <i>Gynecologic Oncology</i> , <b>2016</b> , 142, 158-162	4.9	5
52	HLA-DP4 expression and immunity to NY-ESO-1: correlation and characterization of cytotoxic CD4+ CD25- CD8- T cell clones. <i>Cancer Immunity</i> , <b>2004</b> , 4, 15		5
51	A COMMON PITUITARY AUTOANTIBODY IN TWO PATIENTS WITH IMMUNE CHECKPOINT INHIBITOR-MEDIATED HYPOPHYSITIS: ZCCHC8. <i>AACE Clinical Case Reports</i> , <b>2020</b> , 6, e151-e160	0.7	4
50	Impact of gemcitabine + cisplatin + ipilimumab on circulating immune cells in patients (pts) with metastatic urothelial cancer (mUC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4586-4586	2.2	4
49	A phase I study of the safety and immunogenicity of a multi-peptide personalized genomic vaccine in the adjuvant treatment of solid cancers.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, TPS3114-TPS3114	2.2	4

48	A phase I study of concomitant galinpepimut-s (GPS) in combination with nivolumab (nivo) in patients (pts) with WT1+ ovarian cancer (OC) in second or third remission.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 5553-5553	2.2	4
47	Cytotoxic lymphocytes are dysregulated in multisystem inflammatory syndrome in children <b>2020</b> ,		4
46	Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund's adjuvant (IFA) for resected high-risk melanoma <b>2021</b> , 9,		4
45	Split T-cell tolerance as a guide for the development of tumor antigen-specific immunotherapy. <i>Oncolmmunology</i> , <b>2012</b> , 1, 405-407	7.2	3
44	A phase II open labeled, randomized study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared to Montanide, in melanoma patients in complete clinical remission.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 9538-9538	2.2	3
43	Phase I study of PD-L1 inhibition with avelumab and laser interstitial thermal therapy in patients with recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, TPS2074-TPS2074	2.2	3
42	A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward <b>2020</b> ,		3
41	400 GM-CSF AUTOANTIBODIES PRECEDE THE DEVELOPMENT OF CROHN'S DISEASE AND PREDICT COMPLICATED PHENOTYPE AT DIAGNOSIS. <i>Gastroenterology</i> , <b>2020</b> , 158, S-74	13.3	3
40	Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy <b>2021</b> , 9,		3
39	Fatal breakthrough infection after anti-BCMA CAR-T therapy highlights suboptimal immune response to SARS-CoV-2 vaccination in myeloma patients		3
38	Divergent early antibody responses define COVID-19 disease trajectories <b>2021</b> ,		3
37	Multiplex Tissue Imaging Harmonization: A Multicenter Experience from CIMAC-CIDC Immuno-Oncology Biomarkers Network. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 5072-5083	12.9	3
36	Intratumoral checkpoint subversion as a strategy for minimizing adverse effects: Harvesting the power of TILs without harvesting TILs. <i>Oncolmmunology</i> , <b>2014</b> , 3, e27580	7.2	2
35	A first-in-human phase 1 dose-escalating trial of G305 in patients with solid tumors expressing NY-ESO-1.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3073-3073	2.2	2
34	Association of CMB305 or LV305-induced and baseline anti-NY-ESO-1 immunity with survival in recurrent cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3090-3090	2.2	2
33	Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancer. <i>Oncotarget</i> , <b>2020</b> , 11, 2669-2683	3.3	2
32	Tumoral and immune heterogeneity in an anti-PD-1-responsive glioblastoma: a case study. <i>Journal of Physical Education and Sports Management</i> , <b>2020</b> , 6,	2.8	2
31	Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume II-practical challenges <b>2020</b> , 8,		2

30	Randomized phase II trial of a first-in-human cancer cell lysate vaccine in patients with thoracic malignancies. <i>Translational Lung Cancer Research</i> , <b>2021</b> , 10, 3079-3092	4.4	2
29	Perturb-map enables CRISPR genomics with spatial resolution and identifies regulators of tumor immune composition		2
28	A case of spontaneous systemic immunity to melanoma associated with cure after amputation for extensive regional recurrence. <i>Cancer Immunology, Immunotherapy</i> , <b>2013</b> , 62, 1327-34	7.4	1
27	Protein and DNA-Based Vaccines With the NY-ESO-1 Antigen in Cancer Patients. <i>Journal of Immunotherapy</i> , <b>2005</b> , 28, 659	5	1
26	Integrated Cytof, Scrna-Seq and Cite-Seq Analysis of Bone Marrow Immune Microenvironment in the Mmrf Compass Study. <i>Blood</i> , <b>2020</b> , 136, 28-29	2.2	1
25	Host Immune Responses Against CT Antigens in Multiple Myeloma Patients.. <i>Blood</i> , <b>2006</b> , 108, 3492-3492	2.2	1
24	Phase I/II study of the TLR3 agonist poly-ICLC as an adjuvant for NY-ESO-1 protein vaccination with or without Montanide ISA-51 vg in patients with melanoma.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, TPS9119-TPS9119	2.2	1
23	Window of opportunity trial of HPV E7 antigen-expressing Listeria-based therapeutic vaccination prior to robotic surgery for HPV-positive oropharyngeal cancer.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, TPS6088-TPS6088	2.2	1
22	Single-agent LV305 to induce anti-tumor immune and clinical responses in patients with advanced or metastatic sarcoma and other cancers expressing NY-ESO-1.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3093-3093	2.2	1
21	Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists for resected stage IIB-IV melanoma.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e15171-e15171	2.2	1
20	CIMAC-CIDC tissue imaging harmonization.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3125-3125	2.2	1
19	CIMAC-CIDC CyTOF harmonization.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e15242-e15242	2.2	1
18	Protein Expression Analysis of Melanocyte Differentiation Antigen TRP-2. <i>American Journal of Dermatopathology</i> , <b>2016</b> , 38, 201-7	0.9	1
17	Application of a 27-protein candidate cardiovascular surrogate endpoint to track risk ascendancy and resolution in COVID-19		1
16	Immune Profiling Mass Cytometry Assay Harmonization: Multicenter Experience from CIMAC-CIDC. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 5062-5071	12.9	1
15	Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC). <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 5038-5048	12.9	1
14	A phase II study of atezolizumab and cobimetinib in PD-1/PD-L1 inhibitor resistant or refractory non-small cell lung cancer: ETCTN #10166.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, TPS9638-TPS9638	2.2	0
13	CD3 and CD20 immune cell densities in primary tumors, lymph node metastasis, and recurrent disease samples of head and neck squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 6551-6551	2.2	0

12	Architecture of Sample Preparation and Data Governance of Immuno-Genomic Data Collected from Bone Marrow and Peripheral Blood Samples Obtained from Multiple Myeloma Patients. <i>Blood</i> , <b>2020</b> , 136, 17-18	2.2
11	Identification and Validation of CD138- Multiple Myeloma Immune and Tumor Subpopulations Using Cross Center Scrna-Seq Data. <i>Blood</i> , <b>2020</b> , 136, 15-15	2.2
10	Characterization of Plasma and Immune Cells Molecular Landscape That Play a Role in Rapid Progression of Multiple Myeloma Using Cross Center Scrna-Seq Study. <i>Blood</i> , <b>2020</b> , 136, 6-8	2.2
9	CTIM-09. PHASE I STUDY OF PD-L1 INHIBITION WITH AVELUMAB AND LASER INTERSTITIAL THERMAL THERAPY IN PATIENTS WITH RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , <b>2021</b> , 23, vi51-vi51	
8	Single-Cell RNA-Seq Analysis of CD138-Depleted Bone Marrow Samples Reveals Genetic Alterations and Disease Progression Correlate with Tumor and Bone Marrow Immune Microenvironment in the Mmrf Compass Study. <i>Blood</i> , <b>2021</b> , 138, 2691-2691	2.2
7	510. Elevated IL-1 $\beta$ level as a predictor of inflammation and death in COVID-19. <i>Open Forum Infectious Diseases</i> , <b>2020</b> , 7, S320-S321	1
6	Genomic and Immunologic Analysis of Cmaf and Hypermutated Multiple Myeloma: Implications for Immunologic Therapy. <i>Blood</i> , <b>2019</b> , 134, 3093-3093	2.2
5	Reduced Antigen Presentation May Contribute to Immunomodulatory Drug Resistance in Multiple Myeloma. <i>Blood</i> , <b>2019</b> , 134, 4367-4367	2.2
4	High Dimensional Immune Profiling in Smoldering Multiple Myeloma Identifies Novel Organizing Features of the Tumor Microenvironment. <i>Blood</i> , <b>2019</b> , 134, 4384-4384	2.2
3	Phase I/II study of resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 9086-9086	2.2
2	Poly-ICLC as an adjuvant for NY-ESO-1 protein vaccination with or without Montanide ISA-51 VG in patients with melanoma.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e14034-e14034	2.2
1	Prognostic effects of peripheral and tumor-infiltrating T-cell repertoire diversity in ovarian cancer.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 5546-5546	2.2